PMC6913761_01
The integrative genomics viewer snapshot of HER2 R896G by next-generation sequencing.
OTT-12-10897-g0001.jpg
PMC6913761_01_OTT-12-10897-g0001.jpg
F0001
The sequencing results showed that the patient had a HER2 exon 22 R896G mutation with an allelic fraction of 50.77% (Figure 1).
Computed tomography (CT) scans revealed the tumor response to afatinib. (A) The progressive disease status of lung lesion before afatinib treatment. (B) CT of the chest showing partial response after 2 month of afatinib treatment. CT of the chest showing no progressive disease after (C) 7 months, (D) 11 months and (E) 14 months of afatinib treatment.
OTT-12-10897-g0002.jpg
PMC6913761_01_OTT-12-10897-g0002.jpg
F0002
After the treatment of 2 months, the computed tomography (CT) scan showed that the maximal tumor diameter in the target lesions decreased from 5.61 cm to 3.34 cm with a decrease of 40.5% (Figure 2A and B). Comparing the CT scan in Figure 2B, the maximal tumor diameter in (Figure 2C and 2D) increased from 3.31 cm to 3.64 cm (3.78 cm) with an increase of 9.0% (13.2%). Until September 2019, the latest return visit, no progressive disease had been observed in the patient (Figure 2E).
Computed tomography (CT) scans revealed the changes of the metastatic lesion (A) before afatinib treatment and after (B) 2 month, (C) 7 months, (D) 11 months and (E) 14 months of afatinib treatment. The red dash circle in (A) represents the biggest metastasis lesion.
OTT-12-10897-g0003.jpg
PMC6913761_01_OTT-12-10897-g0003.jpg
F0003
As for the hepatic metastatic lesions, the maximal tumor diameter of the biggest metastasis before afatinib treatment was 3.2 cm (Figure 3A). After afatinib treatment, the CT image suggested that the metastasis lesion had been reduced significantly and become unclear (Figure 3B-E).